初始化项目,由ModelHub XC社区提供模型
Model: DipaHealth/DipaMed-1 Source: Original Platform
This commit is contained in:
104
README.md
Normal file
104
README.md
Normal file
@@ -0,0 +1,104 @@
|
||||
---
|
||||
license: llama3.1
|
||||
base_model: meta-llama/Llama-3.1-8B
|
||||
language:
|
||||
- en
|
||||
pipeline_tag: text-generation
|
||||
tags:
|
||||
- medical
|
||||
- clinical
|
||||
- nigeria
|
||||
- healthcare
|
||||
- africa
|
||||
- llama
|
||||
- global-health
|
||||
---
|
||||
|
||||
# DipaMed-1
|
||||
|
||||
**A language model specialised on Nigerian clinical guidelines.**
|
||||
|
||||
DipaMed-1 adapts Meta's Llama-3.1-8B to Nigerian medicine, grounded in Federal Ministry of Health (FMOH) and Nigeria Centre for Disease Control (NCDC) clinical guidelines. It is built to give locally-appropriate clinical guidance that reflects Nigerian disease priorities, the Nigerian Essential Medicines List, and national treatment protocols.
|
||||
|
||||
- **Developed by:** Destiny Ebhodaghe Ibhate (DipaHealth)
|
||||
- **Base model:** meta-llama/Llama-3.1-8B
|
||||
- **Language:** English
|
||||
- **License:** Llama 3.1 Community License
|
||||
|
||||
> **Intended use:** clinical decision *support* for trained health workers. DipaMed-1 is **not** an autonomous diagnostic system and must not be used to make patient-care decisions without a qualified clinician.
|
||||
|
||||
## Highlights - where DipaMed-1 leads
|
||||
|
||||
On [NigeriaMedQA](https://huggingface.co/datasets/DipaHealth/NigeriaMedQA), DipaMed-1 **outperforms its base model on the Nigeria-specific clinical topics it was built for:**
|
||||
|
||||
| Topic | DipaMed-1 | Base Llama-3.1-8B | Improvement |
|
||||
|---|---|---|---|
|
||||
| Mental health | **95.8%** | 87.5% | **+8.3** |
|
||||
| Maternal emergencies | **90.6%** | 84.4% | **+6.2** |
|
||||
| Drug availability | **72.8%** | 67.0% | **+5.8** |
|
||||
| Hypertension | **68.5%** | 64.8% | **+3.7** |
|
||||
| Tuberculosis-HIV | **82.4%** | 79.4% | **+3.0** |
|
||||
| Lassa fever | **79.5%** | 76.9% | **+2.6** |
|
||||
| Sickle cell disease | **81.8%** | 80.0% | **+1.8** |
|
||||
| Outbreak diseases | **62.1%** | 60.3% | **+1.8** |
|
||||
|
||||
These are the diseases and decisions that matter most in Nigerian practice. Across the full benchmark, DipaMed-1 performs comparably to the base model overall (76.3% vs 77.0%), while delivering these gains where Nigerian specialisation counts.
|
||||
|
||||
## What makes it different
|
||||
|
||||
General medical models are trained on North American and European data. DipaMed-1 is grounded in **Nigerian** guidelines, giving Nigeria-appropriate answers a general model cannot: correct local first-line treatments, Essential-Medicines-List-aware choices, and NCDC/FMOH-aligned protocols.
|
||||
|
||||
## How it was built
|
||||
|
||||
| Stage | Purpose | Data |
|
||||
|---|---|---|
|
||||
| **Continued pretraining** | Absorb Nigerian medical knowledge | 156 million words of Nigerian biomedical text (PubMed abstracts, open-access PMC full-text, clinical guidelines); approx. 254M tokens |
|
||||
| **Instruction tuning** | Learn to answer clinical questions | Q&A generated from and independently verified against real Nigerian guidelines, plus cleaned expert-created sources (PubMedQA, MedQA-USMLE, WikiDoc) |
|
||||
|
||||
Training used QLoRA (rank 16), a learning-rate sweep with model selection on a **held-out validation set**, and completion-only loss masking. The evaluation benchmark was kept fully uncontaminated and used only once for final scoring. The pretraining corpus is not released; its construction methodology is described in the accompanying paper.
|
||||
|
||||
## Usage
|
||||
|
||||
```python
|
||||
import torch
|
||||
from transformers import AutoModelForCausalLM, AutoTokenizer
|
||||
|
||||
model_id = "DipaHealth/DipaMed-1"
|
||||
model = AutoModelForCausalLM.from_pretrained(model_id, torch_dtype=torch.bfloat16, device_map="auto")
|
||||
tok = AutoTokenizer.from_pretrained(model_id)
|
||||
|
||||
messages = [
|
||||
{"role": "system", "content": "You are DipaMed-1, a clinical AI assistant grounded in Nigerian guidelines."},
|
||||
{"role": "user", "content": "First-line treatment for uncomplicated malaria in a non-pregnant adult in Nigeria?"},
|
||||
]
|
||||
input_ids = tok.apply_chat_template(messages, add_generation_prompt=True, return_tensors="pt").to(model.device)
|
||||
out = model.generate(input_ids=input_ids, max_new_tokens=256, do_sample=False, pad_token_id=tok.eos_token_id)
|
||||
print(tok.decode(out[0][input_ids.shape[1]:], skip_special_tokens=True))
|
||||
```
|
||||
|
||||
## Recommended deployment: retrieve, then answer (RAG)
|
||||
|
||||
For production, wrap DipaMed-1 in a retrieval-augmented (RAG) pipeline over the Nigerian guidelines: retrieve the relevant passage, give it to the model, and have it answer **from that passage with a citation**. This substantially improves factual reliability, especially for exact drug doses where all language models are unreliable from memory, and lets the system cite its source. A dedicated DipaMed RAG service is planned as a separate release.
|
||||
|
||||
## Limitations and responsible use
|
||||
|
||||
- **Exact doses:** do not rely on DipaMed-1 for precise dosing without retrieval support; language models do not reliably memorise numeric dose tables.
|
||||
- **Decision support only:** it assists clinicians and must not make autonomous clinical decisions.
|
||||
- **Scale:** at 8B parameters it will not match frontier models on general medicine; its strength is Nigerian domain specialisation.
|
||||
- **Errors and bias:** like all language models it can produce confident but incorrect answers; verify outputs against source guidelines.
|
||||
- **Scope:** English, text-only in this version. Speech and Nigerian-language support are planned.
|
||||
|
||||
## Citation
|
||||
|
||||
```bibtex
|
||||
@misc{dipamed2026,
|
||||
title = {DipaMed-1: A Nigerian Guideline-Specialised Clinical Language Model},
|
||||
author = {Ibhate, Destiny Ebhodaghe},
|
||||
year = {2026},
|
||||
howpublished = {\url{https://huggingface.co/DipaHealth/DipaMed-1}}
|
||||
}
|
||||
```
|
||||
|
||||
## Acknowledgements
|
||||
|
||||
Built on Meta Llama-3.1-8B. Evaluated with [NigeriaMedQA](https://huggingface.co/datasets/DipaHealth/NigeriaMedQA). Grounded in FMOH and NCDC clinical guidelines.
|
||||
Reference in New Issue
Block a user